Earnings Call · Q3 FY2024·2024-08-08

Q3 24EPS -100.00%*·Rev n/aQ2 24EPS -100.00%*·Rev n/aQ1 24EPS -49.40%·Rev n/aQ4 23EPS -70.00%·Rev n/a⚠ consensus missing

ARROWHEAD PHARMACEUTICALS, INC. ARWR

Vince Anzalone — Vice President (likely of Investor Relations or similar)

Chris Anzalone — President and Chief Executive Officer

Bruce Given — Interim Executive (likely Interim Chief Medical Officer)

Andy Davis — Senior Executive (likely Head of Commercial or similar)

Ken Myszkowski — Chief Financial Officer

−9.4%1d on move date−9.9% vs SPY3d−11.6%5d−12.3%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ARWR calls or request research access.

More ARWR calls Browse calls Request research access